MarketInOut Stock Screener Log In | Sign Up
 

Oragenics Inc

NYSE • Healthcare • Biotechnology • Quote as of 08/24/2026 10:05
Oragenics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization2.44 mln
Float4.42 mln
Earnings Date08/07/2026

EPS

0.98
Decent

P / E

0.52
Anomalous

Piotroski F-Score

4 / 9
Borderline

Relative Strength

9 / 100
Severely lagging

Debt / Equity

0.01
Debt-free

ROE

-220
Deeply negative

Business Description

Oragenics is a US-based pharmaceutical company focused on developing treatments for brain and infectious diseases, delivered through the nose rather than by injection or pill. Their primary drug candidate, ONP-002, is a lab-made compound designed to pass through the brain's protective barrier, where it works to reduce swelling and inflammation while improving blood flow in patients with mild traumatic brain injuries. Founded in 1996 and based in Lakewood Ranch, Florida, the company continues to advance its pipeline of therapies through ongoing research and development.

Key Fundamentals

EPS0.98
P/E0.52
ROE-220
ROIC-758
ROA-135
EBITDA, mln-9.40
EV / EBITDA0.38
EV / EBIT0.38

Financial Strength

Piotroski F-Score 4 / 9
Short Ratio28.91
Short % of Float17.33

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -4.47% 13 / 100   
1 Month 0.02% 30 / 100   
2 Months -13.14% 10 / 100   
6 Months -21.03% 9 / 100   
1 Year -52.68% 4 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us